Dr Fraikin developed Spectradyne’s initial Microfluidic Resistive Pulse Sensing technology as part of his PhD thesis work at UC Santa Barbara in the research group of Dr. Andrew Cleland. After graduating he received postdoctoral training in cancer cell biology and biochemistry and worked in industry developing microfluidics-based molecular diagnostics. Dr. Fraikin is a co-founder of Spectradyne and now serves as the company’s CEO.
Spectradyne Technology Overview
Wednesday, 29 May 2024 at 13:05
Add to Calendar ▼2024-05-29 13:05:002024-05-29 14:05:00Europe/LondonSpectradyne Technology OverviewMultivalent Targeted EVs and LNPs: FREE Webinar on EV Engineering in VirtualVirtualSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2024-05-29 00:00:002024-05-29 00:00:00Europe/LondonMultivalent Targeted EVs and LNPs: FREE Webinar on EV EngineeringMultivalent Targeted EVs and LNPs: FREE Webinar on EV Engineering in VirtualVirtualSELECTBIOenquiries@selectbiosciences.com